OMedLive CME Courses
OMedLive CME Courses
This activity is intended for pediatric oncology nurses, pediatric nurses, oncology nurses, nurse practitioners, nurse managers, infusion nurses, research nurses, physician assistants, and other health care providers who care for or have an interest in pediatric patients with high-risk neuroblastoma
Speakers:
Matthew H. Kulke, MD, MMSc, Associate Professor of Medicine, Director of the Neuroendocrine and Carcinoid Tumor Program at Dana-Farber Cancer Institute and a professor of medicine at Harvard Medical School
David C. Metz, MBBCh, is Professor of Medicine at the Perelman School of Medicine (University of Pennsylvania)
Topic and Learning Objectives
- To incorporate evidence-based practices into the management of carcinoid syndrome
- Review the efficacy and safety of treatment programs for carcinoid syndrome
- To summarize the causes of carcinoid syndrome
- Review the differential diagnosis and appropriate workup for the presenting symptoms
This activity is intended for US-based medical oncologists, endocrinologists and gastroenterologists, as well as oncology physician assistants, nurse practitioners, and nurses involved in the diagnosis and management of carcinoid tumors and carcinoid syndrome. Considering the symptoms and potential complications involved in carcinoid syndrome, clinicians in cardiology, dermatology, pulmonary medicine, surgery, radiology (including interventional, diagnostic, and nuclear medicine), internal medicine and primary care may also benefit from education.
TOPICS OF INTEREST:
- Disease- and patient-factors influencing treatment choices at relapse
- Mechanisms of drug resistance and clonal heterogeneity
- Emerging agents: Immunodulatory derivatives, novel pathway targets, second-generation proteasome inhibitors, and monoclonal antibodies
- Drawing on clinical trials of emerging therapies to benefit patients
TOPICS OF INTEREST:
- Clinical data on emerging new agents
- Immunotherapy and chemotherapy selection
- Multimodal therapies
- Clinical trials for bladder cancer
Includes Topics in
- HR deficiencies and BRCA mutations
- Recurrent ovarian cancer
- Data on available and emerging PARP inhibitors
- Personalizing treatment selection
- Companion Diagnostics